Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2023
AbbVie files patent lawsuit against BeiGene over Brukinsa
Lawsuit filed
AbbVie’s Pharmacyclics unit filed a lawsuit against BeiGene in federal court in Delaware, alleging that BeiGene’s Brukinsa infringes a patent on AbbVie’s Imbruvica. AbbVie sought a declaratory judgment of infringement and damages; BeiGene said it would vigorously defend against the allegations.
Company response
Denial — BeiGene
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.
Source excerpt
Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.